Terms: = Liver cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Clinical Outcome
12 results:
1. Development of CD44E/s dual-targeting DNA aptamer as nanoprobe to deliver treatment in hepatocellular carcinoma.
Lo CW; Chan CKW; Yu J; He M; Choi CHJ; Lau JYW; Wong N
Nanotheranostics; 2022; 6(2):161-174. PubMed ID: 34976591
[No Abstract] [Full Text] [Related]
2. Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor outcome in Hepatocellular Carcinoma.
Duan M; Goswami S; Shi JY; Wu LJ; Wang XY; Ma JQ; Zhang Z; Shi Y; Ma LJ; Zhang S; Xi RB; Cao Y; Zhou J; Fan J; Zhang XM; Gao Q
Clin Cancer Res; 2019 Jun; 25(11):3304-3316. PubMed ID: 30723143
[TBL] [Abstract] [Full Text] [Related]
3. Pathological Predictors of Shunt Stenosis and Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt.
He F; Dai S; Xiao Z; Wang L; Yue Z; Zhao H; Zhao M; Lin Q; Dong X; Liu F
Biomed Res Int; 2016; 2016():3681731. PubMed ID: 27975051
[No Abstract] [Full Text] [Related]
4. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma.
Hackl C; Neumann P; Gerken M; Loss M; Klinkhammer-Schalke M; Schlitt HJ
BMC Cancer; 2014 Nov; 14():810. PubMed ID: 25369977
[TBL] [Abstract] [Full Text] [Related]
5. A genetic variant (rs17251221) in the calcium-sensing receptor relates to hepatocellular carcinoma susceptibility and clinical outcome treated by transcatheter hepatic arterial chemoembolization (TACE) therapy.
Tang Q; Zhao Y; Wang Y; Wei M
Med Oncol; 2014 Nov; 31(11):267. PubMed ID: 25270285
[TBL] [Abstract] [Full Text] [Related]
6. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome.
Yopp AC; Mansour JC; Beg MS; Arenas J; Trimmer C; Reddick M; Pedrosa I; Khatri G; Yakoo T; Meyer JJ; Shaw J; Marrero JA; Singal AG
Ann Surg Oncol; 2014 Apr; 21(4):1287-95. PubMed ID: 24318095
[TBL] [Abstract] [Full Text] [Related]
7. Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients.
Marquardt JU; Fischer K; Baus K; Kashyap A; Ma S; Krupp M; Linke M; Teufel A; Zechner U; Strand D; Thorgeirsson SS; Galle PR; Strand S
Hepatology; 2013 Sep; 58(3):1054-64. PubMed ID: 23526469
[TBL] [Abstract] [Full Text] [Related]
8. Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab.
Ricotta R; Vanzulli A; Moroni M; Colnago B; Oriani M; Nichelatti M; Sarnataro C; Venturini F; Di Bella S; Maiolani M; Giganti MO; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2013 Mar; 12(1):45-53. PubMed ID: 23041354
[TBL] [Abstract] [Full Text] [Related]
9. Acute ischemic cholecystitis after transarterial chemoembolization of hepatocellular carcinoma: incidence and clinical outcome.
Wagnetz U; Jaskolka J; Yang P; Jhaveri KS
J Comput Assist Tomogr; 2010; 34(3):348-53. PubMed ID: 20498534
[TBL] [Abstract] [Full Text] [Related]
10. Putative association of fas and fasL gene polymorphisms with clinical outcomes of hepatitis B virus infection.
Jung YJ; Kim YJ; Kim LH; Lee SO; Park BL; Shin HD; Lee HS
Intervirology; 2007; 50(5):369-76. PubMed ID: 17938571
[TBL] [Abstract] [Full Text] [Related]
11. fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract] [Full Text] [Related]
12. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer.
Backus HH; van Riel JM; van Groeningen CJ; Vos W; Dukers DF; Bloemena E; Wouters D; Pinedo HM; Peters GJ
Ann Oncol; 2001 Jun; 12(6):779-85. PubMed ID: 11484952
[TBL] [Abstract] [Full Text] [Related]
